Publications by authors named "Shlomit Amar-Farkash"

Article Synopsis
  • The study compares the effectiveness and safety of combined CTLA-4 and PD-1 blockade therapy to anti-PD-1 monotherapy in treating metastatic melanoma patients.
  • Results indicate no overall survival difference between the two treatments for the entire cohort, but combined therapy showed better results for patients with multi-organ metastasis, while monotherapy was more beneficial for those with oligo-organ metastasis.
  • Patients receiving combination therapy also faced significantly higher hospitalization rates from adverse immune-related events when they had oligo-organ metastasis, highlighting the need for careful treatment selection.
View Article and Find Full Text PDF

Background: FOLFOX (leucovorin calcium [folinic acid], fluorouracil, and oxaliplatin) combined with or without anti-VEGF therapy represents one of the primary first-line treatment options for metastatic colorectal carcinoma (mCRC). However, there is limited comparative data on the impact of anti-VEGF therapy on treatment effectiveness, survival outcomes, and tumor location.

Methods: This retrospective, comparative study utilized data from the AIM Cancer Care Quality Program and commercially insured patients treated at medical oncology clinics in the US.

View Article and Find Full Text PDF

Importance: FOLFIRINOX (leucovorin calcium [folinic acid], fluorouracil, irinotecan hydrochloride, and oxaliplatin) and gemcitabine plus nab-paclitaxel are the 2 common first-line therapies for metastatic adenocarcinoma of the pancreas (mPC), but they have not been directly compared in a clinical trial, and comparative clinical data analyses on their effectiveness are limited.

Objective: To compare the FOLFIRINOX and gemcitabine plus nab-paclitaxel treatments of mPC in clinical data and evaluate whether there are differences in overall survival and posttreatment complications between them.

Design, Setting, And Participants: This retrospective, nonrandomized comparative effectiveness study used data from the AIM Specialty Health-Anthem Cancer Care Quality Program and from administrative claims of commercially insured patients, spanning 388 outpatient centers and clinics for medical oncology located in 44 states across the US.

View Article and Find Full Text PDF

Background: Drugs often kill some cancer cells while others survive. This stochastic outcome is seen even in clonal cells grown under the same conditions. Understanding the molecular reasons for this stochastic outcome is a current challenge, which requires studying the proteome at the single cell level over time.

View Article and Find Full Text PDF